{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:14:58Z","timestamp":1794356098616,"version":"4.9.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/NEU-NMC\/0248\/2012"],"award-info":[{"award-number":["PTDC\/NEU-NMC\/0248\/2012"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/DTP\/04138\/2013"],"award-info":[{"award-number":["UID\/DTP\/04138\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD72891\/2010"],"award-info":[{"award-number":["SFRH\/BPD72891\/2010"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/95855\/2013"],"award-info":[{"award-number":["SFRH\/BPD\/95855\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/98023\/2013"],"award-info":[{"award-number":["SFRH\/BPD\/98023\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.expneurol.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T06:47:46Z","timestamp":1495694866000},"page":"77-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"special_numbering":"C","title":["Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease"],"prefix":"10.1016","volume":"295","author":[{"given":"Sara","family":"Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00edsa","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia Neves","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago F.","family":"Outeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cec\u00edlia Maria Pereira","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Castro-Caldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.expneurol.2017.05.009_bb0005","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1046\/j.1471-4159.1997.69031196.x","article-title":"Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra","volume":"69","author":"Alam","year":"1997","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.expneurol.2017.05.009_bb0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/bies.10067","article-title":"Animal models of Parkinson's disease","volume":"24","author":"Betarbet","year":"2002","journal-title":"BioEssays"},{"issue":"6","key":"10.1016\/j.expneurol.2017.05.009_bb0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bcp.2012.11.016","article-title":"The Nrf2 cell defense pathway: Keap1-dependent and independent mechanisms of regulation","volume":"85","author":"Bryan","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.expneurol.2017.05.009_bb0020","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuro.2006.07.019","article-title":"In vivo modulation of the Parkinsonian phenotype by Nrf2","volume":"27","author":"Burton","year":"2006","journal-title":"Neurotoxicology"},{"issue":"2","key":"10.1016\/j.expneurol.2017.05.009_bb0025","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12035-012-8368-4","article-title":"Ubiquitin-proteasome system impairment and MPTP-induced oxidative stress in the brain of C57BL\/6 wild-type and GSTP knockout mice","volume":"47","author":"Carvalho","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0030","article-title":"Oxidative stress and antioxidants in neurological diseases: is there still hope?","author":"Carvalho","year":"2016","journal-title":"Curr. Drug Targets"},{"issue":"10","key":"10.1016\/j.expneurol.2017.05.009_bb0035","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/1873-3468.12177","article-title":"S-Glutathionylation of Keap1: a new role for glutathione S-transferase pi in neuronal protection","volume":"590","author":"Carvalho","year":"2016","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.expneurol.2017.05.009_bb0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12031-008-9141-z","article-title":"GSTpi expression in MPTP-induced dopaminergic neurodegeneration of C57BL\/6 mouse midbrain and striatum","volume":"38","author":"Castro-Caldas","year":"2009","journal-title":"J. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.expneurol.2017.05.009_bb0045","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12035-012-8295-4","article-title":"Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease","volume":"46","author":"Castro-Caldas","year":"2012","journal-title":"Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.expneurol.2017.05.009_bb0050","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1073\/pnas.0813361106","article-title":"Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"41","key":"10.1016\/j.expneurol.2017.05.009_bb0055","doi-asserted-by":"crossref","first-page":"15091","DOI":"10.1073\/pnas.0607260103","article-title":"DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2","volume":"103","author":"Clements","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.expneurol.2017.05.009_bb0060","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson's disease","volume":"3","author":"Dias","year":"2013","journal-title":"J. Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.expneurol.2017.05.009_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neurobiolaging.2014.08.034","article-title":"Amyloid-\u03b2 pathology is attenuated by tauroursodeoxycholic acid treatment in APP\/PS1 mice after disease onset","volume":"36","author":"Dion\u00edsio","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.expneurol.2017.05.009_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ene.12664","article-title":"Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis","volume":"23","author":"Elia","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/cercor\/bhv268","article-title":"Adenosine A2A receptors modulate \u03b1-synuclein aggregation and toxicity","author":"Ferreira","year":"2015","journal-title":"Cereb. Cortex"},{"issue":"1","key":"10.1016\/j.expneurol.2017.05.009_bb0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1046\/j.1471-4159.1998.70010268.x","article-title":"Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay","volume":"70","author":"Floor","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0085","article-title":"Tauroursodeoxycholic acid protects against mitochondrial dysfunction and cell death via mitophagy in human neuroblastoma cells","author":"Fonseca","year":"2016","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.expneurol.2017.05.009_bb0090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12017-014-8294-x","article-title":"Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease","volume":"16","author":"Gaki","year":"2014","journal-title":"NeuroMolecular Med."},{"issue":"6","key":"10.1016\/j.expneurol.2017.05.009_bb0095","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1460-9568.2010.07138.x","article-title":"Keap1-Nrf2 activation in the presence and absence of DJ-1","volume":"31","author":"Gan","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cotox.2016.10.002","article-title":"The multifaceted role of Nrf2 in mitochondrial function","volume":"1","author":"Holmstr\u00f6m","year":"2016","journal-title":"Curr. Opin. Toxicol."},{"issue":"13","key":"10.1016\/j.expneurol.2017.05.009_bb0105","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/hmg\/dds131","article-title":"DJ-1 induces thioredoxin 1 expression through Nrf2 pathway","volume":"21","author":"Im","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainres.2007.01.131","article-title":"Nrf2-mediated protection against 6-hydroxydopamine","volume":"1144","author":"Jakel","year":"2007","journal-title":"Brain Res."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2017.05.009_bb0115","first-page":"24","article-title":"Oxidative mechanisms in nigral cell death in Parkinson's disease","volume":"13","author":"Jenner","year":"1998","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.expneurol.2017.05.009_bb0120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1353-8020(99)00034-6","article-title":"Genetic susceptibility and the occurrence of Parkinson's disease","volume":"5","author":"Jenner","year":"1999","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0125","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"716871","author":"Keane","year":"2011","journal-title":"Parkinsons Dis."},{"issue":"16","key":"10.1016\/j.expneurol.2017.05.009_bb0130","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1073\/pnas.162362299","article-title":"Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease","volume":"99","author":"Keene","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.expneurol.2017.05.009_bb0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0278-5846(03)00019-8","article-title":"Apoptosis and Parkinson's disease","volume":"27","author":"Lev","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.expneurol.2017.05.009_bb0140","doi-asserted-by":"crossref","first-page":"a008870","DOI":"10.1101\/cshperspect.a008870","article-title":"Clinical approach to Parkinson's disease: features, diagnosis, and principles of management","volume":"2","author":"Massano","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.expneurol.2017.05.009_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"24","author":"Moon","year":"2015","journal-title":"Exp. Neurobiol."},{"issue":"2","key":"10.1016\/j.expneurol.2017.05.009_bb0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.abb.2008.04.003","article-title":"(\u2212)-Epigallocatechin gallate induces Nrf2-mediated antioxidant enzyme expression via activation of PI3K and ERK in human mammary epithelial cells","volume":"476","author":"Na","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"issue":"4\u20136","key":"10.1016\/j.expneurol.2017.05.009_bb0155","first-page":"781","article-title":"Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines","volume":"26","author":"Nagatsu","year":"2006","journal-title":"Cell. Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.expneurol.2017.05.009_bb0160","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12035-012-8256-y","article-title":"TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid beta deposition in APP\/PS1 mice","volume":"45","author":"Nunes","year":"2012","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.expneurol.2017.05.009_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053394","article-title":"Histone deacetylase inhibition decreases cholesterol levels in neuronal cells by modulating key genes in cholesterol synthesis, uptake and efflux","volume":"8","author":"Nunes","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.expneurol.2017.05.009_bb0170","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0304-3940(86)90320-4","article-title":"Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients","volume":"67","author":"Perry","year":"1986","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.expneurol.2017.05.009_bb0175","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0304-3940(82)90390-1","article-title":"Parkinson's disease: a disorder due to nigral glutathione deficiency?","volume":"33","author":"Perry","year":"1982","journal-title":"Neurosci. Lett."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2017.05.009_bb0180","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.parkreldis.2004.10.012","article-title":"Pathogenesis of nigral cell death in Parkinson's disease","author":"Przedborski","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"10.1016\/j.expneurol.2017.05.009_bb0185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1471-4159.2004.02517.x","article-title":"Inhibition of the E2F-1\/p53\/Bax pathway by tauroursodeoxycholic acid in amyloid \u03b2-peptide-induced apoptosis of PC12 cells","volume":"90","author":"Ramalho","year":"2004","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.expneurol.2017.05.009_bb0190","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1471-4159.2006.04007.x","article-title":"Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells","volume":"98","author":"Ramalho","year":"2006","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.expneurol.2017.05.009_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/nen.0b013e31802d6da9","article-title":"Expression of Nrf2 in neurodegenerative diseases","volume":"66","author":"Ramsey","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"6","key":"10.1016\/j.expneurol.2017.05.009_bb0200","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1046\/j.1471-4159.2000.0752368.x","article-title":"Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition","volume":"75","author":"Rodrigues","year":"2000","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.expneurol.2017.05.009_bb0205","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00004647-200204000-00010","article-title":"Neuroprotection by a bile acid in an acute stroke model in the rat","volume":"22","author":"Rodrigues","year":"2002","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0210","doi-asserted-by":"crossref","first-page":"14841","DOI":"10.1074\/jbc.M513737200","article-title":"Glycogen synthase kinase-3\u03b2 inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2","volume":"281","author":"Salazar","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"9\u201312","key":"10.1016\/j.expneurol.2017.05.009_bb0215","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2119\/2003-00042.Rodrigues","article-title":"Tauroursodeoxycholic acid prevents amyloid-\u03b2 peptide\u2013induced neuronal death via a phosphatidylinositol 3-kinase\u2013dependent signaling pathway","volume":"9","author":"Sol\u00e1","year":"2003","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.expneurol.2017.05.009_bb0220","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0006-8993(96)01271-1","article-title":"Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice","volume":"749","author":"Sriram","year":"1997","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.expneurol.2017.05.009_bb0225","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1093\/hmg\/ddm159","article-title":"Parkinson's disease","volume":"16","author":"Thomas","year":"2007","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.expneurol.2017.05.009_bb0230","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/ars.2007.1957","article-title":"Redox regulation of cell survival","volume":"10","author":"Trachootham","year":"2008","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0235","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2007.05.076","article-title":"17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult","volume":"1164","author":"Tripanichkul","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0240","article-title":"The Nrf2\/ARE pathway: a promising target to counteract mitochondrial dysfunction in Parkinson's disease","volume":"314082","author":"Tufekci","year":"2011","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0245","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1471-4159.2009.06054.x","article-title":"Inducible over-expression of wild type \u03b1-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death","volume":"109","author":"Vekrellis","year":"2009","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.expneurol.2017.05.009_bb0250","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.freeradbiomed.2008.09.001","article-title":"Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?","volume":"45","author":"de Vries","year":"2008","journal-title":"Free Radic. Biol. Med."},{"issue":"6","key":"10.1016\/j.expneurol.2017.05.009_bb0255","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1046\/j.1471-4159.2003.02123.x","article-title":"Over-expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults","volume":"87","author":"Wang","year":"2003","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.expneurol.2017.05.009_bb0260","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lfs.2014.08.004","article-title":"Gastrodin prevents motor deficits and oxidative stress in the MPTP mouse model of Parkinson's disease: involvement of ERK1\/2-Nrf2 signaling pathway","volume":"114","author":"Wang","year":"2014","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.expneurol.2017.05.009_bb0265","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.neuro.2012.01.015","article-title":"Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity","volume":"33","author":"Williamson","year":"2012","journal-title":"Neurotoxicology"},{"issue":"1","key":"10.1016\/j.expneurol.2017.05.009_bb0270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbadis.2009.08.013","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"1802","author":"Winklhofer","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.expneurol.2017.05.009_bb0275","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1073\/pnas.93.7.2696","article-title":"Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease","volume":"93","author":"Yoritaka","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.expneurol.2017.05.009_bb0280","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0002-9440(10)65396-5","article-title":"Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons","volume":"154","author":"Zhang","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0285","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pneurobio.2012.09.003","article-title":"Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection","volume":"100","author":"Zhang","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2017.05.009_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.190","article-title":"Zeaxanthin induces Nrf2-mediated phase II enzymes in protection of cell death","volume":"5","author":"Zou","year":"2014","journal-title":"Cell Death Dis."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488617301267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488617301267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T02:51:23Z","timestamp":1655952683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488617301267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":58,"alternative-id":["S0014488617301267"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2017.05.009","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}